BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 21090963)

  • 1. The Fabry cardiomyopathy: models for the cardiologist.
    Weidemann F; Niemann M; Warnock DG; Ertl G; Wanner C
    Annu Rev Med; 2011; 62():59-67. PubMed ID: 21090963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiological follow-up in patients with Fabry disease].
    Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
    G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabry disease and the heart.
    Seydelmann N; Wanner C; Störk S; Ertl G; Weidemann F
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):195-204. PubMed ID: 25987173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fabry disease: treatment and diagnosis.
    Rozenfeld PA
    IUBMB Life; 2009 Nov; 61(11):1043-50. PubMed ID: 19859978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
    Breunig F; Wanner C
    J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
    Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
    Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
    Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
    J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anderson-Fabry disease and the heart.
    O'Mahony C; Elliott P
    Prog Cardiovasc Dis; 2010; 52(4):326-35. PubMed ID: 20109602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
    Wang RY; Abe JT; Cohen AH; Wilcox WR
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Management of Fabry disease].
    Constantin T; Székely A; Ponyi A; Gulácsy V; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Medvecz M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Rákóczi E; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G
    Orv Hetil; 2010 Aug; 151(31):1243-51. PubMed ID: 20656661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Fabry cardiomyopathy - diagnostic approach and current treatment.
    Weidemann F; Ertl G; Wanner C; Krämer J
    Curr Pharm Des; 2015; 21(4):473-8. PubMed ID: 25483948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Clinical-Pathologic Results of Enzyme Replacement Therapy in Prehypertrophic Fabry Disease Cardiomyopathy.
    Frustaci A; Verardo R; Galea N; Alfarano M; Magnocavallo M; Marchitelli L; Sansone L; Belli M; Cristina M; Frustaci E; Russo MA; Chimenti C
    J Am Heart Assoc; 2024 Apr; 13(8):e032734. PubMed ID: 38563373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.
    Putko BN; Wen K; Thompson RB; Mullen J; Shanks M; Yogasundaram H; Sergi C; Oudit GY
    Heart Fail Rev; 2015 Mar; 20(2):179-91. PubMed ID: 25030479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.
    Spinelli L; Pisani A; Sabbatini M; Petretta M; Andreucci MV; Procaccini D; Lo Surdo N; Federico S; Cianciaruso B
    Clin Genet; 2004 Aug; 66(2):158-65. PubMed ID: 15253767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early therapeutic intervention in females with Fabry disease?
    Hughes DA
    Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature.
    Thurberg BL; Politei JM
    Hum Pathol; 2012 Apr; 43(4):610-4. PubMed ID: 22078290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fabry disease in cardiology: Diagnosis and therapeutic approaches].
    Çavuşoğlu Y; Özpelit E; Arslan N; Demir M; Kahveci G; Onay H; Ökçün EÖB; Tufekcioglu O; Tülüce SY; Yıldırım GK
    Turk Kardiyol Dern Ars; 2020 Dec; 48(Suppl 2):1-42. PubMed ID: 33476309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fabry disease.
    Yuasa T; Takenaka T; Higuchi K; Uchiyama N; Horizoe Y; Cyaen H; Mizukami N; Takasaki K; Kisanuki A; Miyata M; Ohishi M
    J Echocardiogr; 2017 Dec; 15(4):151-157. PubMed ID: 28674962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interdisciplinary approach towards female patients with Fabry disease.
    Weidemann F; Niemann M; Sommer C; Beer M; Breunig F; Wanner C
    Eur J Clin Invest; 2012 Apr; 42(4):455-62. PubMed ID: 22049975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.